智通财经APP获悉，香港联交所最新资料显示，8月15日，CSCEC CAPITAL(HONG KONG)LIMITED减 持光大证券(06178)417.1万股，每股作价11.6936港元，总金额约为4877.4万港元。减持后最新持股数目 约为1.18亿股，最新持股比例为16.70%。 ...

Market Performance - The Shanghai Composite Index reached a new high of 3741.29 points, the highest since August 2015, with a closing increase of 1.18% at 3740.5 points [1][2] - The Shenzhen Component Index and the ChiNext Index both surpassed their previous highs from October 2024, with increases of 2.25% and 3.63% respectively [2] Market Capitalization and Trading Volume - The total market capitalization of A-shares exceeded 110 trillion yuan, reaching 113 trillion yuan, marking a historical high [2] - The trading volume in the market surpassed 1 trillion yuan, with a morning trading volume of 17.221 billion yuan, an increase of 4.114 billion yuan compared to the previous trading day [2] Sector Performance - The film and cinema sector saw significant gains, with companies like Baidu and Huace Film & TV hitting the daily limit [4][5] - The internet finance sector also experienced strong performance, with stocks like Longcheng Securities and Zhinanceng rising sharply [6][7] - Technology stocks rebounded across the board, particularly in the computing industry chain, with significant gains in liquid cooling server stocks and AI-related sectors [8][9] Investment Trends - There is a notable trend of funds migrating from deposits to the stock market, driven by declining deposit rates and increasing financial investment awareness among the private sector [10] - Analysts suggest that the "rain and dew evenly distributed" approach in the market indicates that sectors like finance and technology will continue to perform well [11]

Core Viewpoint - Tianmai Technology (300807.SZ) reported significant revenue growth in the first half of 2025, but continued to incur net losses, indicating ongoing financial challenges despite improved performance metrics [1][2]. Financial Performance - The company achieved operating revenue of 66.38 million yuan in the first half of 2025, representing an 82.79% increase compared to 36.32 million yuan in the same period last year [2]. - The net profit attributable to shareholders was -4.27 million yuan, an improvement of 87.21% from -33.40 million yuan year-on-year [2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -7.86 million yuan, a 76.94% improvement from -34.07 million yuan in the previous year [2]. - The net cash flow from operating activities was -2.28 million yuan, showing an 81.21% improvement from -12.15 million yuan year-on-year [2]. Historical Performance - Tianmai Technology has reported losses for four consecutive years, with operating revenues of 233 million yuan, 329 million yuan, 220 million yuan, and 164 million yuan from 2021 to 2024 respectively [2]. - The net profit attributable to shareholders for the same years were -37.27 million yuan, -8.51 million yuan, -50.07 million yuan, and -59.31 million yuan [2]. - The net profit after deducting non-recurring gains and losses for the same period were -49.81 million yuan, -20.90 million yuan, -54.87 million yuan, and -60.83 million yuan [2]. - The net cash flow from operating activities varied significantly, with figures of -91.88 million yuan, 20.22 million yuan, -40.30 million yuan, and 8.44 million yuan over the same years [2]. IPO Information - Tianmai Technology was listed on the Shenzhen Stock Exchange's Growth Enterprise Market on December 19, 2019, issuing 17 million shares at a price of 17.68 yuan per share [3]. - The total amount raised from the initial public offering (IPO) was 301 million yuan, with a net amount of 261 million yuan after expenses [3]. - The actual net fundraising amount was 1.25 billion yuan less than the originally planned net amount of 386 million yuan, which was intended for projects related to the Internet of Things and working capital [3].

Core Insights - The main business segments of Everbright Securities include securities brokerage, investment banking, securities investment, and asset management, with wealth management being the largest revenue contributor at 49.53% [3] - Everbright Securities achieved a net profit attributable to shareholders of 30.58 billion yuan in 2024, reflecting a cumulative growth of 8.20% since its listing in 2009, with no annual losses recorded over the 16 years [3] - The company's revenue has shown a declining trend, with 158.66 billion yuan in 2020 dropping to 95.98 billion yuan in 2024 [4] - The net profit attributable to shareholders increased from 23.34 billion yuan in 2020 to 30.58 billion yuan in 2024, indicating overall profit growth despite fluctuations [5] - Since its listing, Everbright Securities' market value has decreased, with a peak market value of 1433.95 billion yuan in July 2020, dropping to 883.43 billion yuan by August 2020, representing a market value loss of 550.53 billion yuan or 38.39% [7]

中国经济网北京8月15日讯昨日，上海光大证券资产管理有限公司发布关于上海光大证券资产管理有限 公司旗下产品估值调整的公告。 根据《中国证券监督管理委员会关于证券投资基金估值业务的指导意见》(证监会公告[2017]13号)的要 求，经与托管人协商一致，自2025年8月13日起，上海光大证券资产管理有限公司(以下简称"本公司") 对旗下资产管理计划持有的"诺辉健康(证券代码：6606.HK)"按照0.01港元/股进行估值。 ...

| 代码 | 名称 | | 涨跌幅 ▽ | 最新价 | 总市值 | | --- | --- | --- | --- | --- | --- | | 01375 | 中州证券 | (0) | 12.27% | 3.110 | 144.39亿 | | 06066 | 中信建投证券 | | 9.30% | 14.930 | 1158.07亿 | | 01456 | 国联民生 | | 8.61% | 7.190 | 408.43 Z | | 06881 | 中国银河 | | 8.25% | 12.330 | 1348.21 Z | | 03908 | 中金公司 | | 8.31% | 22.940 | 1107.37亿 | | 06099 | 招商证券 | | 6.80% | 18.700 | 1626.25亿 | | 06030 | 中信证券 | | 6.22% | 31.100 | 4609.19 Z | | 03678 | 3777888 | | 6.05% | 5.080 | 51.2亿 | | 06178 | 光大证券 | | 5.08% | 11.800 | 544.07亿 | | 02611 | 国泰海 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 承董事會命 光大證券股份有限公司 董事長 光大證券股份有限公司 Everbright Securities Company Limited （於中華人民共和國註冊成立的股份有限公司） （股份代號：6178） 董事會會議召開日期 光大證券股份有限公司（「本公司」）董事會（「董事會」）謹此宣佈，董事會將於 2025年8月28日（星期四）舉行董事會會議，藉以審議及批准本公司及其附屬公司 截至2025年6月30日止六個月未經審計的中期業績、考慮派發中期股息（如有） 及╱或其他議題（如適用）。 趙陵 中國上海 2025年8月14日 於本公告日期，本公司董事會成員包括趙陵先生（董事長、執行董事）、劉秋明 先生（執行董事、總裁）、馬韌韜女士（非執行董事）、連涯鄰先生（非執行董事）、 潘劍雲先生（非執行董事）、尹岩武先生（非執行董事）、秦小徵先生（非執行董 事）、任永平先生（獨立非執行董事）、殷俊明先生（獨立非執行董事 ...

诚达药业首次公开发行股票的发行费用总额为13,576.31万元，其中，保荐承销费用11,792.90万元。 2023年7月3日，诚达药业发布2022年度权益分派实施公告。公司2022年年度权益分派方案为：以公司现 有总股本96,696,140股为基数，向全体股东每10股派3.000000元人民币现金，同时，以资本公积金向全 体股东每10股转增6.000000股。本次权益分派股权登记日为2023年7月6日，除权除息日为2023年7月7 日。 诚达药业首次公开发行股票募集资金总额为175,721.06万元，扣除发行费用后募集资金净额162,144.75万 元。诚达药业实际募资净额比原拟募集资金多110,816.71万元。诚达药业于2022年1月14日披露的招股说 明书显示，该公司原拟募集资金51,328.04万元，分别用于"医药中间体项目、原料药项目及研发中心扩 建项目"和"补充流动资金"。 中国经济网北京8月14日讯诚达药业（301201）(301201.SZ)今日股价下跌，截至收盘报27.34元，跌幅 5.50%，该股目前处于破发状态。 诚达药业于2022年1月20日在深交所创业板上市，公开发行新股2,417 ...

Core Viewpoint - Everbright Securities (06178.HK) will hold a board meeting on August 28, 2025, to review and approve the group's interim results for the six months ending June 30, 2025, and to consider the proposal for an interim dividend distribution if applicable [1] Group 1 - The board meeting is scheduled for August 28, 2025 [1] - The meeting will focus on the interim results for the six months ending June 30, 2025 [1] - The proposal for an interim dividend distribution will be reviewed during the meeting [1]

Group 1 - The company Shanghai Everbright Securities Asset Management Co., Ltd. will value its asset management plans holding "Nohow Health (stock code: 6606.HK)" at HKD 0.01 per share starting from August 13, 2025 [1] - The company will closely monitor the subsequent operational status and other significant matters related to the stock for reasonable assessment [1] - The valuation method will revert to using the closing price of the day once the stock demonstrates active market trading characteristics, without further announcements [1]